SYRS Insider Trading
Insider Ownership Percentage: 12.26%
Insider Buying (Last 12 Months): $206,490.57
Insider Selling (Last 12 Months): $225,493.85
Syros Pharmaceuticals Insider Trading History Chart
This chart shows the insider buying and selling history at Syros Pharmaceuticals by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Syros Pharmaceuticals Share Price & Price History
Current Price: $0.03
Price Change: ▼ Price Decrease of -0.0033 (-10.86%)
As of 03/28/2025 04:59 PM ET
Syros Pharmaceuticals Insider Trading History
SEC Filings (Institutional Ownership Changes) for Syros Pharmaceuticals (NASDAQ:SYRS)
91.47% of Syros Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.
Institutional Buying and Selling by Quarter
This chart shows the instiutional buying and selling at SYRS by year and by quarter.
Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
Syros Pharmaceuticals Institutional Trading History
Data available starting January 2016
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
Read More on Syros Pharmaceuticals
Volume
640,593 shs
Average Volume
8,051,844 shs
Market Capitalization
$727,147.20
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.31
Who are the company insiders with the largest holdings of Syros Pharmaceuticals?
Who are the major institutional investors of Syros Pharmaceuticals?
Which major investors are selling Syros Pharmaceuticals stock?
During the previous quarter, SYRS stock was sold by these institutional investors:
- Citadel Advisors LLC
- FNY Investment Advisers LLC
In the last year, company insiders that have sold Syros Pharmaceuticals company stock include:
- Srinivas Akkaraju (Director)
- Jason Haas (CFO)
- Conley Chee (CEO)
Learn More investors selling Syros Pharmaceuticals stock.
Which major investors are buying Syros Pharmaceuticals stock?
In the previous quarter, SYRS stock was bought by institutional investors including:
- Affinity Asset Advisors LLC
- Two Sigma Securities LLC
- Torno Capital LLC
During the previous year, these company insiders have bought Syros Pharmaceuticals stock:
- Srinivas Akkaraju (Director)
- Jason Haas (CFO)
- Conley Chee (CEO)
Learn More investors buying Syros Pharmaceuticals stock.